Loading...
ICCC logo

ImmuCell CorporationNasdaqCM:ICCC Stock Report

Market Cap US$52.5m
Share Price
US$5.80
n/a
1Y25.8%
7D-4.8%
Portfolio Value
​
View

ImmuCell Corporation

NasdaqCM:ICCC Stock Report

Market Cap: US$52.5m

ImmuCell (ICCC) Stock Overview

An animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. More details

ICCC fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance3/6
Financial Health6/6
Dividends0/6

Rewards

Became profitable this year

Risk Analysis

Does not have a meaningful market cap ($52M)


ICCC Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View Stock Community

ImmuCell Corporation Competitors

Price History & Performance

Summary of share price highs, lows and changes for ImmuCell
Historical stock prices
Current Share PriceUS$5.80
52 Week HighUS$7.60
52 Week LowUS$4.28
Beta0.21
1 Month Change22.88%
3 Month Change-4.05%
1 Year Change25.81%
3 Year Change-5.84%
5 Year Change-3.17%
Change since IPO480.00%

Recent News & Updates

ImmuCell Corporation's (NASDAQ:ICCC) Price Is Right But Growth Is Lacking After Shares Rocket 34%

Dec 18
ImmuCell Corporation's (NASDAQ:ICCC) Price Is Right But Growth Is Lacking After Shares Rocket 34%

These 4 Measures Indicate That ImmuCell (NASDAQ:ICCC) Is Using Debt Reasonably Well

Nov 15
These 4 Measures Indicate That ImmuCell (NASDAQ:ICCC) Is Using Debt Reasonably Well

Recent updates

ImmuCell Corporation's (NASDAQ:ICCC) Price Is Right But Growth Is Lacking After Shares Rocket 34%

Dec 18
ImmuCell Corporation's (NASDAQ:ICCC) Price Is Right But Growth Is Lacking After Shares Rocket 34%

These 4 Measures Indicate That ImmuCell (NASDAQ:ICCC) Is Using Debt Reasonably Well

Nov 15
These 4 Measures Indicate That ImmuCell (NASDAQ:ICCC) Is Using Debt Reasonably Well

Why Investors Shouldn't Be Surprised By ImmuCell Corporation's (NASDAQ:ICCC) Low P/S

Oct 18
Why Investors Shouldn't Be Surprised By ImmuCell Corporation's (NASDAQ:ICCC) Low P/S

ImmuCell (NASDAQ:ICCC) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Aug 22
ImmuCell (NASDAQ:ICCC) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

We Think ImmuCell (NASDAQ:ICCC) Can Stay On Top Of Its Debt

May 22
We Think ImmuCell (NASDAQ:ICCC) Can Stay On Top Of Its Debt

ImmuCell Corporation (NASDAQ:ICCC) Stock Catapults 28% Though Its Price And Business Still Lag The Industry

Dec 04
ImmuCell Corporation (NASDAQ:ICCC) Stock Catapults 28% Though Its Price And Business Still Lag The Industry

ImmuCell (NASDAQ:ICCC) Is Making Moderate Use Of Debt

Nov 30
ImmuCell (NASDAQ:ICCC) Is Making Moderate Use Of Debt

Revenues Working Against ImmuCell Corporation's (NASDAQ:ICCC) Share Price

Aug 07
Revenues Working Against ImmuCell Corporation's (NASDAQ:ICCC) Share Price

ImmuCell (NASDAQ:ICCC) Is Making Moderate Use Of Debt

Aug 10
ImmuCell (NASDAQ:ICCC) Is Making Moderate Use Of Debt

Insufficient Growth At ImmuCell Corporation (NASDAQ:ICCC) Hampers Share Price

May 27
Insufficient Growth At ImmuCell Corporation (NASDAQ:ICCC) Hampers Share Price

ImmuCell GAAP EPS of -$0.09, revenue of $3.86M

Aug 11

ImmuCell announces preliminary 2Q sales of $3.9M

Jul 07

Health Check: How Prudently Does ImmuCell (NASDAQ:ICCC) Use Debt?

Sep 15
Health Check: How Prudently Does ImmuCell (NASDAQ:ICCC) Use Debt?

Why We Think Shareholders May Be Considering Bumping Up ImmuCell Corporation's (NASDAQ:ICCC) CEO Compensation

Jun 10
Why We Think Shareholders May Be Considering Bumping Up ImmuCell Corporation's (NASDAQ:ICCC) CEO Compensation

Is ImmuCell (NASDAQ:ICCC) Using Too Much Debt?

Mar 15
Is ImmuCell (NASDAQ:ICCC) Using Too Much Debt?

Does ImmuCell's (NASDAQ:ICCC) Share Price Gain of 38% Match Its Business Performance?

Jan 22
Does ImmuCell's (NASDAQ:ICCC) Share Price Gain of 38% Match Its Business Performance?

Shareholder Returns

ICCCUS BiotechsUS Market
7D-4.8%3.3%3.1%
1Y25.8%26.7%14.6%

Return vs Industry: ICCC matched the US Biotechs industry which returned 25.9% over the past year.

Return vs Market: ICCC exceeded the US Market which returned 14.2% over the past year.

Price Volatility

Is ICCC's price volatile compared to industry and market?
ICCC volatility
ICCC Average Weekly Movement7.8%
Biotechs Industry Average Movement11.3%
Market Average Movement6.4%
10% most volatile stocks in US Market16.7%
10% least volatile stocks in US Market3.0%

Stable Share Price: ICCC has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: ICCC's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
198281P. F. Te Boekhorstimmucell.com

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments: Scours and Mastitis. The company offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus.

ImmuCell Corporation Fundamentals Summary

How do ImmuCell's earnings and revenue compare to its market cap?
ICCC fundamental statistics
Market capUS$52.47m
Earnings (TTM)US$2.32m
Revenue (TTM)US$27.77m
22.6x
P/E Ratio
1.9x
P/S Ratio

Is ICCC overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ICCC income statement (TTM)
RevenueUS$27.77m
Cost of RevenueUS$16.00m
Gross ProfitUS$11.77m
Other ExpensesUS$9.45m
EarningsUS$2.32m

Last Reported Earnings

Sep 30, 2025

Next Earnings Date

Feb 25, 2026

Earnings per share (EPS)0.26
Gross Margin42.40%
Net Profit Margin8.37%
Debt/Equity Ratio31.8%

How did ICCC perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/12/24 12:56
End of Day Share Price 2025/12/24 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

ImmuCell Corporation is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Nathan WeinsteinAegis Capital Corporation